Gilead Sciences (GILD) PT Lowered to $82 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Gilead Sciences (GILD), Galapagos NV (GLPG) Report Filgotinib Demonstrates Durable Efficacy & Consistent Safety Profile at 52-Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis
June 4, 2020 6:09 AM EDTGilead Sciences, Inc. (NASDQ: GILD) and Galapagos NV (NASDAQ: GLPG) today announced Week 52 results from the Phase 3 FINCH 1 and FINCH 3 studies of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately to severely active rheumatoid arthritis (RA). The data demonstrate sustained efficacy and a consistent safety profile with up to 52 weeks of filgotinib treatment across RA patient populations. The new data are among 15 abstracts on filgotinib in RA that will be presented at the European League Against Rheumatism, EULAR, European E-Congress of Rheumatology... More
